All In Biotech

Drug Trial Radar · NCT02231749

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,096 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,096

Actual

Start

Oct 16, 2014

Primary completion

Jun 26, 2017

Study completion Mar 21, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Sep 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

Conditions

  • Advanced Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma

Interventions

  • NivolumabBiological

  • IpilimumabBiological

  • SunitinibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in Intermediate/Poor Risk Participants Per Independent Radiology Review Committee (IRRC) Using RECIST v1.1Time frame: From first dose until date of documented disease progression or subsequent therapy, whichever occurs first (assessed up to June 2017, approximately 31 months)
  2. Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)Time frame: From the date of randomization to the date of death (assessed up to June 2017, approximately 31 months)
  3. Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)Time frame: From date of first dose to date of documented disease progression or death due to any cause, whichever occurs first (assessed up to June 2017, approximately 31 months)

Locations

189 sites in 28 countries. Site status is shown where the registry gives one.

  • Local Institution - 0006

    Duarte, California

  • Local Institution - 0057

    La Jolla, California

  • Local Institution - 0044

    Los Angeles, California

  • Local Institution - 0035

    Los Angeles, California

  • Local Institution - 0067

    Stanford, California

  • Local Institution - 0138

    New Haven, Connecticut

  • Local Institution - 0034

    Washington D.C., District of Columbia

  • Local Institution - 0049

    Tampa, Florida

  • Local Institution - 0068

    Atlanta, Georgia

  • Local Institution - 0038

    Indianapolis, Indiana

  • Local Institution - 0042

    Iowa City, Iowa

  • Local Institution - 0163

    Fairway, Kansas

  • Local Institution - 0048

    Baltimore, Maryland

  • Local Institution - 0004

    Baltimore, Maryland

  • Local Institution - 0135

    Boston, Massachusetts

  • Local Institution - 0110

    Boston, Massachusetts

  • Local Institution - 0161

    Boston, Massachusetts

  • Local Institution - 0173

    Boston, Massachusetts

  • Local Institution - 0046

    Ann Arbor, Michigan

  • Local Institution - 0043

    Detroit, Michigan

  • Local Institution - 0036

    Buffalo, New York

  • Local Institution - 0001

    New York, New York

  • Local Institution - 0008

    Charlotte, North Carolina

  • Local Institution - 0045

    Durham, North Carolina

  • Local Institution - 0007

    Cleveland, Ohio

  • Local Institution - 0164

    Columbus, Ohio

  • Local Institution - 0039

    Portland, Oregon

  • Local Institution - 0054

    Allentown, Pennsylvania

  • Local Institution - 0005

    Philadelphia, Pennsylvania

  • Local Institution - 0031

    Pittsburgh, Pennsylvania

  • Local Institution - 0055

    Charleston, South Carolina

  • Local Institution - 0159

    Chattanooga, Tennessee

  • Local Institution - 0066

    Nashville, Tennessee

  • Local Institution - 0056

    Dallas, Texas

  • Local Institution - 0032

    Dallas, Texas

  • Local Institution - 0003

    Houston, Texas

  • Local Institution - 0041

    Seattle, Washington

  • Local Institution - 0097

    CABA, Argentina

  • Local Institution - 0100

    Córdoba, Argentina

  • Local Institution - 0099

    Berazategui, Buenos Aires, Argentina

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.